Daehwa Pharm will present phase 3 results of Liporaxel Sol. in breast cancer at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Daehwa Pharm said Monday that the clinical results will be presented by the study's Coordinating Investigator (CI), Professor Kim Sung-bae of the Department of Medical Oncology at Asan Medical Center, at the ASCO 2025 Oral Abstract Session from May 30 to June 3 in Chicago, USA.

The presentation will focus on results from a multinational, multicenter, phase 3 trial in patients with recurrent or metastatic HER2-negative breast cancer.

Liporaxel is the world's first oral formulation of the poorly soluble paclitaxel. At ASCO 2025, Daehwa Pharm plans to showcase Liporaxel's superiority in the global oncology market and further solidify its potential for global success.

ASCO is one of the world's three major cancer societies, along with the American Association for Cancer Research (AACR) and the European Society for Medical Oncology (ESMO). It holds annual conferences to share the latest cancer research achievements and treatment strategies. Each year, ASCO attracts more than 40,000 global pharmaceutical representatives and healthcare professionals from around the world.